Pacemaker-associated infection caused by ST81/SCCmec IV methicillin-resistant, vancomycin-intermediate Staphylococcus aureus in Japan

M. Sakurada1, H. Sumi1, K. Kaji1, N. Kobayashi2, Y. Sakai3, M. S. Aung4, N. Urushibara4 and N. Kobayashi4
1) Department of Pharmacy, 2) Department of Laboratory, 3) Department of Paediatrics, Hakodate Municipal Hospital, Hakodate and 4) Department of Hygiene, Sapporo Medical University School of Medicine, Sapporo, Japan

Abstract

A 76-year-old Japanese man was admitted to hospital for treatment of fever and skin lesion at the implantation site of his pacemaker. During his hospitalization, vancomycin-intermediate Staphylococcus aureus (MIC 4 μg/mL) with reduced susceptibility to daptomycin was isolated from venous blood. This isolate was identified as methicillin-resistant S. aureus with SCCmec IV and was genotyped as sequence type 81, coa VIIa and spa type t7044, harbouring blzA, aac(6′)-aph(2′) and enterotoxin(-like) genes sea, seb, sek, sel, selx and selw. The patient was successfully treated with daptomycin, minocycline and sulfamethoxazole/trimethoprim. We describe the identification of sequence type 81/SCCmec IV vancomycin-intermediate S. aureus from pacemaker-associated septicemia.

Corresponding author: N. Kobayashi, Department of Hygiene, Sapporo Medical University School of Medicine, S-1 W-17, Chuo-ku, Sapporo, 060-8556, Japan.
E-mail: nkobayashi@sapmed.ac.jp

Introduction

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of nosocomial infections worldwide. MRSA has a genetic element SCCmec in its chromosome which has been classified into several types. Generally, SCCmec of hospital-acquired MRSA is mostly assigned to types I to IV, while community-acquired MRSA is assigned to types IV and V [1]. A glycopeptide antibiotic, such as vancomycin (VCM), is one of the representative anti-MRSA drugs and is frequently used as first-choice therapy to treat MRSA infections. However, VCM intermediate-resistant S. aureus (VISA) was first reported in Japan in 1996 [2]. VISA is defined as S. aureus showing VCM MIC of 4 to 8 μg/mL, according to Clinical and Laboratory Standards Institute criteria [3]. Despite its low incidence, VISA has been detected worldwide, and it poses a growing public health concern [4]. Occurrence of VISA is considered to be related to persistent infections and prolonged hospitalization with the provision of VCM [5]. In Japan, although prevalence is extremely low, VISA has been identified for SCCmec II-MRSA [6]. SCCmec IV—sequence type (ST) 8 MRSA [7] and SCCmec IV-ST72 MRSA [8]. Here we report the detection of VISA with SCCmec IV-ST81 from a case of pacemaker-associated septicemia.

Case report

A 76-year-old Japanese man was transferred to our hospital. He was suspected to have bacteraemia and pacemaker-associated infection. Because he had fever (temperature 39.2°C) associated with redness and swelling that appeared in the skin of the pacemaker implantation site on the left chest wall, ceftriaxone and VCM had been administered by a former doctor, although no bacterial examination had been performed. The patient had a pacemaker implanted when he was 72 years old for bradycardic atrial fibrillation, and haemodialysis had been performed for chronic renal failure.

At admission (day 1), physical examinations showed the following: blood pressure 116/83 mm Hg, body temperature 37.5°C, respiratory rate 20 breaths/min, heart rate 86 beats/min (arrhythmia/self-pulse), SpO2 92%, clear consciousness (JCS0, GCS15), no rale in breathing sound, flat and soft abdomen and no muscular defense. Blood tests revealed an increase in white blood cell count (11.7 × 109/L), C-reactive protein (13.34 mg/dL) and procalcitonin (27.66 ng/mL).

MRSA was isolated from venous blood on days 1 and 2, as well as from the pacemaker (surface in contact with wounded
part, atrial and ventricular lead wires) on day 9, when the pacemaker was removed. Treatment with ceftriaxone and VCM was continued, but ceftriaxone was discontinued on day 6 after hospitalization, and VCM was administered until day 27. Blood culture results were negative on day 21. Surgery to reimplant the pacemaker was carried out on day 42; the postoperative course was uneventful, but slight fever persisted. On day 48, the patient had a temperature of 38.4°C, and blood culture revealed the presence of MRSA. Therefore, VCM was readministered on day 50. However, the patient’s platelet count decreased, and MRSA isolated from blood samples taken on day 50 showed VCM MIC $2\,\mu$g/mL. VCM was changed to daptomycin (DAP). On day 61, increased VCM MIC, to 4 $\mu$g/mL, was observed for the MRSA isolate grown from blood taken on day 58, so minocycline and sulfamethoxazole/trimethoprim were added to the treatment. On day 63, negative blood culture was confirmed; DAP and minocycline were discontinued on day 73. Because the inflammatory reaction continued, teicoplanin (TEC) was administered for 12 days from day 81. Thereafter the patient fully recovered, without recurrence for 3 months. The MRSA isolated on day 61 (strain HV2019-1) was confirmed to be VISA by MIC measured by broth microdilution test using Dry Plate ‘Eiken’ (192 plate), E-EP02 (Eiken Chemical, Tokyo, Japan). This strain exhibited slightly higher MICs than TEC and DAP (2 $\mu$g/mL each) than those isolated at admission (day 1) until day 9 (Table 1). Accordingly, this strain was judged to be nonsusceptible to DAP. The VISA strain was resistant to penicillin, cephalosporins, aminoglycosides and quinolones while being susceptible to macrolides, clindamycin, linezolid and sulfamethoxazole/trimethoprim. Except for VCM, TEC and DAP, strain HV2019-1 showed the same susceptibility pattern to those of MRSA isolated on days 1 and 9. The SCCmec type of strain HV2019-1 was identified as IV according to multiple PCR by using previously published primers and conditions [9]. Strain HV2019-1 belonged to ST81 (clonal complex (CC) 1) based on the scheme of multilocus sequencing typing [10]. Coagulase genotype (coa) Villa, spa type $\psi$044 and agr type III. Virulence determinants and drug resistance genes were detected by uniplex/multiplex PCR as described previously [11]. Although PVL genes (lukS-PV-lukF-PV) and ACME (arginine catabolic mobile element)-arcA were negative, this strain harbored the enterotoxin-(like) genes sea, seb, sek, sel, selx and selw, as well as epidermal differentiation factor A gene (edin-A) and blaZ and aac(6’)-aph(2’)).

### Discussion

In the present study, genetic information of early MRSA isolates (days 1, 2 and 9) were not available. However, these MRSA isolates showed the same susceptibility patterns (except for VCM, TEC and DAP) to that of VISA strain HV2019-1, thus suggesting that HV2019-1 might be derived from the early MRSA isolated from blood and pacemaker, which presumably remained in any part of patient’s body after treatment with VCM. Occurrence of VISA and its precursor, hetero-VISA (h-VISA), has been an obstacle in chemotherapy of MRSA infections. Globally, the most prevalent genotype of methicillin-resistant VISA is SCCmec II and III, and ST239 and ST5 [3]. Although other STs—ST72, ST59 and ST900—have also been found as less common types in VISA or VISA [5], ST81 (CC 1) has never been detected. Thus, our present study is to our knowledge the first to report ST81 VISA, which was associated with SCCmec IV, a minor SCCmec type among VISA. ST81 *S. aureus* is rarely detected in human clinical isolates [11–13]; there is only a single report of ST81 MRSA that had the same genetic traits (SCCmec IV, coa-Villa/agr-Ill) and similar spa type (c127, repeat profile 07-23-21-16-34-33-13) [11] to that of our present VISA strain. In contrast, ST81 methicillin-susceptible *S. aureus* appears to be commonly distributed in cows with or without mastitis and in rats in Japan [14,15].

### Table 1. Genotypes, antimicrobial susceptibility, virulence factors and other genetic traits of VISA strain HV2019-1

| Characteristic | Value |
|----------------|-------|
| **Genotype**   | coa Villa, MLST ST81, CC1, spa $\psi$044, agr III, SCCmec IV, subtype-nontypeable (class B-mec, ccrA2B2) |
| **Susceptibility pattern** | Resistant to DAP, Susceptible to VCM, TEC, DAP |
| **MIC (\(\mu\)g/mL)** | MRSA/VISA | $<0.5–1/4$ |
| **Virulence factor** | Haemolysin hla, hlb, hlg, hlg |
| **Enterotoxin** | sea, sec, sel, sel, selw |
| **Leukocidin** | luke, luke, luke, luke |
| **Other** | edna, iak |
| **Resistance genes** | blaZ, aac(6’)-aph(2’)) |

**Abbreviations:** ABK, arbekacin; AMK, amikacin; ATM, azithromycin; CC, clonal complex; CIP, ciprofloxacin; CLX, ciprofloxacin; CML, clindamycin; CLR, chloramphenicol; DAP, daptomycin; ERY, erythromycin; FOI, fosfomycin; GEN, gentamicin; GRX, garenoxacin; LVX, levofloxacin; LZX, linezolid; MIN, minocycline; MLST, multilocus sequence typing; MRSA, methicillin-resistant *Staphylococcus aureus*; SXT, sulfamethoxazole/trimethoprim; TEC, teicoplanin; VISA, vancomycin-intermediate *S. aureus*. 

---

© 2020 The Author(s). Published by Elsevier Ltd. NMNI, 35, 1006656

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
We noted that the DAP MIC of the strain HV2019-1 increased and became nonsusceptible (associated with the occurrence of VISA on day 61) shortly after the provision of DAP. Similarly, DAP nonsusceptibility was reported for ST72 VISA (MRSA-IV) in Japan [8]. Reduced susceptibility to vancomycin in S. aureus has been revealed to be generated by accumulation of mutations in various genes represented by rpoB [2]. In case of nonsusceptibility to DAP, point mutations in mprF are associated [16]. One study indicated that a single mutation in mprF was related to reduced susceptibility to both vancomycin and DAP in vitro [17], which was also observed for a clinical MRSA isolate [18]. Therefore, it may be necessary to pay attention to provide DAP to patients with VISA infection.

In conclusion, we here present the isolation of ST81 VISA (MRSA-IV) from pacemaker-associated septicemia. The findings underscore the careful monitoring of susceptibility to vancomycin and DAP for MRSA frequently isolated from patients with underlying diseases.

**Conflict of Interest**

None declared.

**Acknowledgements**

Supported in part by Japan Society for the Promotion of Science Kakenhi grant 17H04664. The authors thank M. Kimura, Y. Nobata, Y. Enami, T. Kohama and K. Nakashima, members of the infection control team at Hakodate Municipal Hospital, for their assistance.

**References**

[1] Bal AM, Coombs GW, Holden MTG, Lindsay JA, Nimmo GR, Tattevin P, et al. Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated meticillin-resistant Staphylococcus aureus: blurring of the traditional definitions. J Glob Antimicrob Resist 2016;6:95–101.

[2] Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135–6.

[3] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne, PA: Clinical and Laboratory Standards Institute; 2015. 24th informational supplement M100-S25.

[4] Hiramatsu K, Kayayama Y, Matsuo M, Aiba Y, Saito M, Hishinuma T, et al. Vancomycin-intermediate resistance in Staphylococcus aureus. J Glob Antimicrob Resist 2014;2:213–24.

[5] Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS One 2015;10:e0136082.

[6] Hanaki H, Hososaka Y, Yanagisawa C, Otsuka Y, Nagasawa Z, Nakae T, et al. Occurrence of vancomycin-intermediate–resistant Staphylococcus aureus in Japan. J Infect Chemother 2007;13:118–21.

[7] Kino H, Suzuki H, Yamaguchi T, Notake S, Oishi T, Ito Y, et al. Central nervous system infection caused by vancomycin-intermediate Staphylococcus aureus (SCCmec type IV, ST8). J Infect Chemother 2014;20:643–6.

[8] Tsukimori A, Nakamura I, Okamura S, Sato A, Fukushima S, Matuno Y, et al. First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin. BMC Infect Dis 2014;14:459.

[9] Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, et al. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob Agents Chemother 2007;51:264–74.

[10] Enright MC, Day NP, Davies CE, Pesceok SJ, Spratt BG. Mutlocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000;38:1008–15.

[11] Aung MS, Urushibara N, Kawaguchiya M, Sumi A, Shinagawa M, Takahashi S, et al. Clonal diversity and genetic characteristics of methicillin-resistant Staphylococcus aureus isolates from a tertiary care hospital. J Microb Drug Resist 2019;25:1164–75.

[12] Piao C, Karasawa T, Totsuka K, Uchiyama T, Kikuchi K. Prospective surveillance of community-onset and healthcare-associated methicillin-resistant Staphylococcus aureus isolated from a university-affiliated hospital in Japan. Microbiol Immunol 2005;49:959–70.

[13] Chongtrakool P, Ito T, Ma XX, Kondo Y, Trakulsomboon S, Tiensastorn C, et al. Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements. Antimicrob Agents Chemother 2006;50:1001–12.

[14] Hata E, Katsuda K, Kobayashi H, Uchida I, Tanaka K, Eguchi M. Genetic variation among Staphylococcus aureus strains from bovine milk and their relevance to methicillin-resistant isolates from humans. J Clin Microbiol 2010;48:2130–9.

[15] PubMLST. Staphylococcus aureus MLST databases. https://pubmlst.org/bigsdb/db&equals;pubmlst_sauureus_isolates&amp;page=&equals; profiles.

[16] Ernst CM, Pescheil A. MprF-mediated daptomycin resistance. Int J Med Microbiol 2019;309:359–63.

[17] Chen FJ, Lauderdale TL, Lee CH, Hsu YC, Huang IW, Hsu PC, et al. Effect of a point mutation in mprF on susceptibility to daptomycin, vancomycin, and oxacillin in an MRSA clinical strain. Front Microbiol 2018;9:1086.

[18] Wuthrich D, Cuénod A, Hinic V, Morgenstern M, Khanna N, Egli A, et al. Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline. J Antimicrob Chemother 2019;74:1452–4.